Zenas BioPharma (ZBIO) Assets Average (2024 - 2026)

Zenas BioPharma's Assets Average history runs 3 years deep, the most recent figure standing at $565.7 million for Q1 2026.

• In Q1 2026, Assets Average rose 60.76% year-over-year to $565.7 million; the TTM figure through Mar 2026 stood at $565.7 million (up 60.76% YoY), while the FY2025 annual figure was $376.8 million, up 72.0% from the prior year.
• Assets Average was $565.7 million for Q1 2026 at Zenas BioPharma, up from $352.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $565.7 million in Q1 2026 to a low of $307.6 million in Q3 2025.
• Historically, Assets Average has averaged $379.7 million across 3 years, with a median of $352.3 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Assets Average declined 8.76% in 2025, then jumped 60.76% in 2026.
• A 3-year view of Assets Average shows it stood at $386.7 million in 2024, then slipped by 8.76% to $352.8 million in 2025, then surged by 60.32% to $565.7 million in 2026.
• The last three Assets Average figures came in at $565.7 million (Q1 2026), $352.8 million (Q4 2025), and $307.6 million (Q3 2025), per Business Quant data.